A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

NCT02421211 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Simeprevir (SMV)
DRUG: Ledipasvir (LDV)
DRUG: Sofosbuvir (SOF)

Sponsor

Janssen Sciences Ireland UC